<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143165</url>
  </required_header>
  <id_info>
    <org_study_id>20/10/2019</org_study_id>
    <nct_id>NCT04143165</nct_id>
  </id_info>
  <brief_title>Ultrasound Guided Epidural Block in Axial SPA</brief_title>
  <official_title>Ultrasound Guided Epidural Block in Axial SPA Patient With Limited Spine Mobility: a Prospective Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design: A randomized, prospective, pilot, controlled trial. Setting: Rheumatology and
      rehabilitation department Minia University and Sohag University Objectives: To evaluate the
      effectiveness of caudal epidural injections with triamcinolone and lidocaine in managing
      limited spine mobility in axial SPA.

      Methods: Patients were randomly assigned to one of 2 groups, Group I patients received caudal
      epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1
      mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip), whereas Group II patients
      did not receive. Both groups were age and sex matched and both were under treatment with anti
      TNF and NSAIDs with or without sDMARDs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2019</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">January 12, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in pain</measure>
    <time_frame>Baseline, after 2 weeks and after 8 weeks</time_frame>
    <description>visual analogue scale for pain minimum score 0 maximum score 10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in functional ability of the patient</measure>
    <time_frame>Baseline, after 2 weeks and after 8 weeks</time_frame>
    <description>Bath Ankylosing Spondylitis Functional Index (BASFI) minimum score 0 maximum 100, Oswestry Disability Index (ODI) minimum 0 no disability, maximum 100 means complete disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spinal mobility</measure>
    <time_frame>Baseline, after 2 weeks and after 8 weeks</time_frame>
    <description>Bath AS Metrology Index (BASMI) minimum score 0 maximum 50, modified Schober test less than 5 cm yield means limited mobility, Lateral lumbar flexion more than 55 cm yield means limited lateral flexion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ASDAS- CRP score</measure>
    <time_frame>Baseline, after 2 weeks and after 8 weeks</time_frame>
    <description>â‰¥ 1.1 reduction in the initial score, less than 1.3 inactive disease, between 1.3 and 2.1 moderate, between 2.1-3.5 high disease activity, &gt; 3.5 very high disease activty</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Epidural Block in Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Epidural block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I patients received caudal epidural injections with 1% lidocaine hydrochloride (xylocaine Astra Zeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients did not receive injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural block with lidocaine and triamcinilone</intervention_name>
    <description>caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)</description>
    <arm_group_label>Epidural block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all participants fulfilled the ASAS criteria for axial SPA

          -  all participants under treatment including bDMARDS and sDMARDs beside NSAIDs

        Exclusion Criteria:

          -  Naive patients not under treatment

          -  limitation of spine flexion due to non inflammatory causes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sohag university</name>
      <address>
        <city>Sohag</city>
        <zip>82749</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahrous</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The consent form does not include this item</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

